Published in Int Clin Psychopharmacol on September 01, 2010
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Optimal treatment of social phobia: systematic review and meta-analysis. Neuropsychiatr Dis Treat (2012) 0.83
Psychometric validation study of the liebowitz social anxiety scale - self-reported version for Brazilian Portuguese. PLoS One (2013) 0.81
Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord (2012) 0.80
Active stimulation site of nucleus accumbens deep brain stimulation in obsessive-compulsive disorder is localized in the ventral internal capsule. Acta Neurochir Suppl (2013) 2.06
Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry (2005) 1.80
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry (2004) 1.57
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol (2003) 1.36
Autonomic and neuroendocrine responses to a psychosocial stressor in adults with autistic spectrum disorder. J Autism Dev Disord (2006) 1.26
Altered pain processing in veterans with posttraumatic stress disorder. Arch Gen Psychiatry (2007) 1.22
Thinner prefrontal cortex in veterans with posttraumatic stress disorder. Neuroimage (2008) 1.12
Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry (2004) 1.12
Symptom dimensions in OCD: item-level factor analysis and heritability estimates. Behav Genet (2010) 1.10
Wireless implantable micro-stimulation device for high frequency bilateral deep brain stimulation in freely moving mice. J Neurosci Methods (2012) 1.06
Glutamate and anxiety. Eur Neuropsychopharmacol (2004) 1.05
The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry (2004) 1.04
Neural correlates of associative learning and memory in veterans with posttraumatic stress disorder. J Psychiatr Res (2007) 1.04
A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry (2004) 1.03
Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry (2002) 1.02
Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder. Psychiatry Res (2004) 0.98
Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review. Int Clin Psychopharmacol (2006) 0.98
Deep brain stimulation reveals a dissociation of consummatory and motivated behaviour in the medial and lateral nucleus accumbens shell of the rat. PLoS One (2012) 0.94
Symptom dimensions in obsessive-compulsive disorder: factor analysis on a clinician-rated scale and a self-report measure. Psychopathology (2004) 0.93
Sympathetic activity and hypothalamo-pituitary-adrenal axis activity during sleep in post-traumatic stress disorder: a study assessing polysomnography with simultaneous blood sampling. Psychoneuroendocrinology (2012) 0.92
Effect of a pharmacological intervention on quality of life in patients with obsessive-compulsive disorder. Int Clin Psychopharmacol (2003) 0.92
Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study. Biol Psychiatry (2005) 0.91
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry (2014) 0.90
Precuneal activity during encoding in veterans with posttraumatic stress disorder. Prog Brain Res (2008) 0.90
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry (2007) 0.88
Effects of dietary tryptophan variations on extracellular serotonin in the dorsal hippocampus of rats. Psychopharmacology (Berl) (2003) 0.88
Female hormones affect symptom severity in obsessive-compulsive disorder. Int Clin Psychopharmacol (2006) 0.87
Reduced sensitivity in the recognition of anger and disgust in social anxiety disorder. Cogn Neuropsychiatry (2006) 0.87
Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. J Affect Disord (2004) 0.87
Sensory gating and sensorimotor gating in medication-free obsessive-compulsive disorder patients. Int Clin Psychopharmacol (2010) 0.87
Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res (2005) 0.87
Assessment of DSM-IV personality disorders in obsessive-compulsive disorder: comparison of clinical diagnosis, self-report questionnaire, and semi-structured interview. J Pers Disord (2003) 0.87
Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats. Biol Psychiatry (2006) 0.87
Attention and cognition in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci (2007) 0.86
Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull (2010) 0.85
Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care. J Psychopharmacol (2003) 0.84
Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol (2009) 0.84
Sexual pleasure in women with obsessive-compulsive disorder? J Affect Disord (2006) 0.82
Spatial working memory in obsessive-compulsive disorder improves with clinical response: A functional MRI study. Eur Neuropsychopharmacol (2006) 0.82
Extracellular serotonin in the prefrontal cortex is limited through terminal 5-HT(1B) autoreceptors: a microdialysis study in knockout mice. Psychopharmacology (Berl) (2002) 0.81
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J Clin Psychiatry (2009) 0.81
The role of the COMT Val(158)Met polymorphism in the phenotypic expression of obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2010) 0.81
Obstructive sleep apnea in combat-related posttraumatic stress disorder: a controlled polysomnography study. Eur J Psychotraumatol (2011) 0.81
Electroconvulsive therapy has acute immunological and neuroendocrine effects in patients with major depressive disorder. J Affect Disord (2010) 0.81
Behavioral pattern analysis and dopamine release in quinpirole-induced repetitive behavior in rats. J Psychopharmacol (2010) 0.80
Role of 5-HT1B receptors in the regulation of extracellular serotonin and dopamine in the dorsal striatum of mice. Eur J Pharmacol (2003) 0.80
Neuroendocrine and immune responses to a cognitive stress challenge in veterans with and without PTSD. Eur J Psychotraumatol (2012) 0.80
Annual incidence rate of schizophrenia and schizophrenia spectrum disorders in a longitudinal population-based cohort study. Soc Psychiatry Psychiatr Epidemiol (2013) 0.80
Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol (2003) 0.80
Association between serotonergic candidate genes and specific phenotypes of obsessive compulsive disorder. J Affect Disord (2006) 0.80
Compulsivity in mouse strains homologous with chromosomes 7p and 15q linked to obsessive-compulsive disorder. Am J Med Genet B Neuropsychiatr Genet (2010) 0.79
The effects of selective serotonin reuptake inhibitors on extracellular 5-HT levels in the hippocampus of 5-HT(1B) receptor knockout mice. Eur J Pharmacol (2002) 0.79
Neuropsychological performance is related to current social and occupational functioning in veterans with posttraumatic stress disorder. Depress Anxiety (2009) 0.79
Signaling pathways involved in Ca2+- and Pb2+-induced vesicular catecholamine release from rat PC12 cells. Brain Res (2002) 0.79
Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study. J Clin Psychiatry (2005) 0.79
Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol (2005) 0.78
Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology (2009) 0.78
Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats. Int J Neuropsychopharmacol (2006) 0.78
Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade. Psychopharmacology (Berl) (2003) 0.78
Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo. J Psychiatr Res (2008) 0.78
An evaluation of the effect of NAS-181, a new selective 5-HT(1B) receptor antagonist, on extracellular 5-HT levels in rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.77
The influence of amphetamine on language activation: an fMRI study. Psychopharmacology (Berl) (2005) 0.77
Latent class analysis of the Yale-Brown Obsessive-Compulsive Scale symptoms in obsessive-compulsive disorder. Compr Psychiatry (2010) 0.77
Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) (2004) 0.77
Bupropion for patients with obsessive-compulsive disorder: an open-label, fixed-dose study. J Clin Psychiatry (2005) 0.77
Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract (2009) 0.76
Marked inbred mouse strain difference in the expression of quinpirole induced compulsive like behavior based on behavioral pattern analysis. Eur Neuropsychopharmacol (2012) 0.76
Effects of paroxetine and venlafaxine on immune parameters in patients with obsessive compulsive disorder. Psychoneuroendocrinology (2005) 0.76
Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls. Eur Neuropsychopharmacol (2004) 0.76
Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude. Int J Neuropsychopharmacol (2009) 0.76
Serotonergic functioning in children with oppositional defiant disorder: a sumatriptan challenge study. Biol Psychiatry (2002) 0.75
Does Insight Affect the Efficacy of Antipsychotics in Acute Mania?: An Individual Patient Data Regression Meta-Analysis. J Clin Psychopharmacol (2016) 0.75
Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Int J Psychiatry Clin Pract (2012) 0.75
Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol (2011) 0.75
Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia. J Clin Psychopharmacol (2002) 0.75
Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder. Int Clin Psychopharmacol (2007) 0.75